Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-06-27

Clinical Trial Update: Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for Abrilumab (AMG 181) in adults with moderate to severe Crohn's disease; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Abrilumab (AMG 181)

Snippet

Sponsor: Amgen | Conditions: Crohn's Disease | Phase 2 | Status: COMPLETED | Results posted: 2019-06-27